These agents target immune checkpoints like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 or its ligand (PD-1/PD-L1), disrupting immunosuppressive pathways and immune homeostasis critical for cancer progression (4–6). Here, CTLA4 is linked to cancer.